Moreover, NSCLC patients with PD-L1− on tissues but PD-L1+ on CTCs could still benefit from ICI therapy, while co-identification of PD-L1+CTCs or PD-L1+ tissues may help to identify patients who would benefit from immunotherapy [56]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.